On Wednesday, Zydus, the pharmaceuticals major has announced receipt of approval to sell chronic pain reliever morphine sulfate tablets from the USFDA (US Food and Drug Administration).

The Cadila Healthcare, which is a part of Zydus group said in a BSE filing that “The product used in treatment of chronic pain or cancer related pain will be manufactured at Nesher Pharmaceuticals (USA) LLC, located at St Louis”.

It further added that a subsidiary of Zydus Pharmaceuticals Inc, Nesher has considerable expertise in niche therapies with development or products barrier, such as controlled release medications.

Know the best stocks to buy